middle.news
NeuroScientific Advances StemSmart™ Trials with New Leadership and Manufacturing Scale-Up
9:19am on Thursday 30th of October, 2025 AEDT
•
Biotechnology
Read Story
NeuroScientific Advances StemSmart™ Trials with New Leadership and Manufacturing Scale-Up
9:19am on Thursday 30th of October, 2025 AEDT
Key Points
TGA approval for first patients in Special Access Program for fistulising Crohn’s disease
Appointment of Dr Catherine Cole as Chief Medical Officer and Nathan Smith as CEO
Partnership with Q-Gen Cell Therapies to scale StemSmart™ manufacturing
Historical data supports StemSmart™ potential in renal transplantation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE